Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multicenter phase II trial ALTER-G-001-cohort C

被引：0
|
作者：
Wu, J. [1 ]
Zhou, C. [1 ]
Yan, J. [2 ]
Han, Z. [3 ]
Wang, C. [2 ,5 ]
Qin, Z. [4 ]
Jiang, J. [1 ]
Wang, C. [2 ,5 ]
Tang, X. [6 ]
Zhu, L. [7 ]
Chen, J. [8 ]
Mao, Y. [9 ]
Wei, X. [10 ]
Shangguan, C. [1 ]
Zhang, J. [1 ]
机构：
[1] Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Oncol, Sch Med, Shanghai, Peoples R China
[2] Jiading Cent Hosp, Dept Oncol, Shanghai, Peoples R China
[3] Xuzhou Med Univ, Affiliated Hosp, Dept Oncol, Xuzhou, Jiangsu, Peoples R China
[4] Zhejiang Prov Peoples Hosp, Dept Oncol, Hangzhou, Peoples R China
[5] 3 Peoples Hosp Yancheng, Dept Oncol, Yancheng, Peoples R China
[6] Ruijin Hosp, Wuxi Branch, Dept Oncol, Wuxi, Jiangsu, Peoples R China
[7] Nanjing Med Univ, Affiliated Hosp 1, Jiangsu Prov Hosp, Dept Oncol, Nanjing, Peoples R China
[8] Ningbo Univ, Affiliated Peoples Hosp, Dept Oncol, Ningbo, Peoples R China
[9] Jiangnan Univ, Wuxi Peoples Hosp 4, Dept Oncol, Wuxi, Jiangsu, Peoples R China
[10] Nanjing First Hosp, Dept Oncol, Nanjing, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.285
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
150P
引用
收藏
页码：S1533 / S1533
页数：1
相关论文
共 50 条
  • [21] ALTER-C-001: Efficacy and safety of anlotinib plus XELOX regimen as first-line treatment followed by maintenance monotherapy of anlotinib for patients with mCRC-A single-arm, multicenter, phase II clinical trial.
    Yan Jin
    Zhang Li
    Jin Yongdong
    Han Yunwei
    Sun Hao
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [22] CETUXIMAB PLUS MFOLFOX-6 AS FIRST-LINE THERAPY FOR UNRESECTABLE LIVER METASTASIS FROM COLORECTAL CANCER: AN OPEN, NON-RANDOMIZED, MULTICENTER PHASE II CLINICAL TRIAL
    Cai, S.
    Zhang, W.
    Li, W.
    Xu, Y.
    Gu, W.
    Guan, Z.
    Cai, J.
    Song, C.
    Xu, J.
    Chi, P.
    ANNALS OF ONCOLOGY, 2012, 23 : 217 - 217
  • [23] Impact of early tumor shrinkage on quality of life in patients treated with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: results of Phase II QUACK trial
    Akira Ooki
    Satoshi Morita
    Akihito Tsuji
    Shigeyoshi Iwamoto
    Hiroki Hara
    Hiroaki Tanioka
    Hironaga Satake
    Masato Kataoka
    Masahito Kotaka
    Yoshinori Kagawa
    Masato Nakamura
    Tatsushi Shingai
    Masashi Ishikawa
    Yasuhiro Miyake
    Takeshi Suto
    Yojiro Hashiguchi
    Taichi Yabuno
    Masahiko Ando
    Junichi Sakamoto
    Kensei Yamaguchi
    BMC Cancer, 22
  • [24] Impact of early tumor shrinkage on quality of life in patients treated with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: results of Phase II QUACK trial
    Ooki, Akira
    Morita, Satoshi
    Tsuji, Akihito
    Iwamoto, Shigeyoshi
    Hara, Hiroki
    Tanioka, Hiroaki
    Satake, Hironaga
    Kataoka, Masato
    Kotaka, Masahito
    Kagawa, Yoshinori
    Nakamura, Masato
    Shingai, Tatsushi
    Ishikawa, Masashi
    Miyake, Yasuhiro
    Suto, Takeshi
    Hashiguchi, Yojiro
    Yabuno, Taichi
    Ando, Masahiko
    Sakamoto, Junichi
    Yamaguchi, Kensei
    BMC CANCER, 2022, 22 (01)
  • [25] Penpulimab (Anti-PD-1) combined with anlotinib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Updated results from a phase Ib/II study.
    Jiao Shun Chang
    Bai Li
    Dong Jiahong
    Bai Chunmei
    Hu Chunhong
    Shen Liangfang
    Qin Qun
    Bai Yuxian
    Fan Jia
    Zang Aimin
    Zhu Yanyun
    Han Chun
    Li Juan
    Zhang Pengfei
    Ye Sisi
    Kang Xindan
    Qiao Qian
    Wang, Zhongmin Maxwell
    Li Baiyong
    Xia Yu
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [26] A multicenter, randomized, phase II trial of anlotinib plus docetaxel versus docetaxel in EGFR-negative NSCLC patients after progression on first-line platinum-base chemotherapy: ALTER-L018.
    Wu, Lin
    Wu, Zhijun
    Xiao, Zemin
    Ma, Zhongsha
    Weng, Jie
    Chen, Yanhua
    Cao, Yongqing
    Cao, Peiguo
    Xiao, Maoliang
    Zhang, Hui
    Duan, Huaxin
    Wang, Qianzhi
    Li, Jia
    Xu, Yan
    Pu, Xingxiang
    Li, Kang
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [27] Gemcitabine (G) plus cisplatin (C) is a highly active regimen in first-line treatment of metastatic breast cancer (MBC): Results of a multicenter phase II trial
    Fuentes, H
    Calderillo, G
    Alexander, F
    Ramirez, M
    Avila, E
    Perez, L
    Aguirre, C
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S72 - S72
  • [28] Anlotinib combined with penpulimab as first-line treatment for persistent, recurrent, or metastatic cervical cancer: Preliminary results from ALTER-GO-020, a single-arm, open-label, multi-cohort, multi-center phase II clinical study.
    Wang, Dengfeng
    Liu, Hong
    Chen, Lihong
    He, Mian
    Zhao, Weidong
    Xiang, Yang
    Zhang, Guonan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [29] Updated results from the multicenter phase II study of fruquintinib plus mFOLFOX6/FOLFIRI as first-line therapy in advanced metastatic colorectal cancer (mCRC)
    Zhou, F.
    Wang, W.
    Xia, L.
    Dai, J.
    Wu, H.
    Yang, L.
    Gong, J.
    Chen, X.
    Xiong, Z.
    Liang, X.
    ANNALS OF ONCOLOGY, 2023, 34 : S439 - S439
  • [30] A phase III trial-in-progress comparing tislelizumab plus chemotherapy with placebo plus chemotherapy as first-line therapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.
    Xu, Rui-hua
    Arkenau, Hendrik-Tobias
    Bang, Yung-Jue
    Denlinger, Crystal S.
    Kato, Ken
    Tabernero, Josep
    Wang, Jin
    Li, Jiang
    Castro, Henry
    Moehler, Markus Hermann
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345